News
Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...
A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...
23h
Zacks Investment Research on MSNNVO Stock up on Plans to Advance Obesity Candidate AmycretinNovo Nordisk NVO announced plans to advance amycretin, for weight management, into late-stage development. Amycretin is being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results